Jung Yoon Choi1,2, Hyoung Jin Kang3,4, Kyung Taek Hong1,2, Che Ry Hong1,2, Yun Jeong Lee1, June Dong Park1, Ji Hoon Phi5, Seung-Ki Kim5, Kyu-Chang Wang5, Il Han Kim2,6, Sung-Hye Park7, Young Hun Choi8, Jung-Eun Cheon8, Kyung Duk Park1,2, Hee Young Shin1,2. 1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea. 2. Seoul National University Cancer Research Institute, Seoul, Republic of Korea. 3. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea. kanghj@snu.ac.kr. 4. Seoul National University Cancer Research Institute, Seoul, Republic of Korea. kanghj@snu.ac.kr. 5. Division of Pediatric Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea. 7. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 8. Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: High-dose chemotherapy (HDC) and autologous stem-cell transplantation (auto-SCT) are used to improve the survival of children with high-risk brain tumors who have a poor outcome with the standard treatment. This study aims to evaluate the outcome of HDC/auto-SCT with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin (TTC/MEC) regimens in pediatric brain tumors. METHODS: We retrospectively analyzed the data of 33 children (median age 6 years) who underwent HDC/auto-SCT (18 tandem and 15 single) with uniform conditioning regimens. RESULTS: Eleven patients aged < 3 years at diagnosis were eligible for HDC/auto-SCT to avoid or defer radiotherapy. In addition, nine patients with high-risk medulloblastoma (presence of metastasis and/or postoperative residual tumor ≥ 1.5 cm2), eight with other high-risk brain tumor (six CNS primitive neuroectodermal tumor, one CNS atypical teratoid/rhabdoid tumor, and one pineoblastoma), and five with relapsed brain tumors were enrolled. There were three toxic deaths, and two of which were due to pulmonary complications. The main reason for not performing tandem auto-SCT was due to toxicities and patient refusal. The event-free survival (EFS) and overall survival (OS) rates of all patients were 59.4% and 80.0% at a median follow-up with 49.1 months from the first HDC/auto-SCT, respectively. The EFS/OS rates of patients aged < 3 years at diagnosis, high-risk medulloblastoma, other high-risk brain tumor, and relapsed tumors were 50.0/81.8%, 87.5/85.7%, 66.7/88.9%, and 20.0/60.0%, respectively. CONCLUSIONS: Although tandem HDC/auto-SCT with TTC/MEC regimens showed promising survival rates, treatment modifications are warranted to reduce toxicities. The survival rates with relapsed brain tumors were unsatisfactory despite HDC/auto-SCT, and further study is needed.
BACKGROUND: High-dose chemotherapy (HDC) and autologous stem-cell transplantation (auto-SCT) are used to improve the survival of children with high-risk brain tumors who have a poor outcome with the standard treatment. This study aims to evaluate the outcome of HDC/auto-SCT with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin (TTC/MEC) regimens in pediatric brain tumors. METHODS: We retrospectively analyzed the data of 33 children (median age 6 years) who underwent HDC/auto-SCT (18 tandem and 15 single) with uniform conditioning regimens. RESULTS: Eleven patients aged < 3 years at diagnosis were eligible for HDC/auto-SCT to avoid or defer radiotherapy. In addition, nine patients with high-risk medulloblastoma (presence of metastasis and/or postoperative residual tumor ≥ 1.5 cm2), eight with other high-risk brain tumor (six CNS primitive neuroectodermal tumor, one CNS atypical teratoid/rhabdoid tumor, and one pineoblastoma), and five with relapsed brain tumors were enrolled. There were three toxic deaths, and two of which were due to pulmonary complications. The main reason for not performing tandem auto-SCT was due to toxicities and patient refusal. The event-free survival (EFS) and overall survival (OS) rates of all patients were 59.4% and 80.0% at a median follow-up with 49.1 months from the first HDC/auto-SCT, respectively. The EFS/OS rates of patients aged < 3 years at diagnosis, high-risk medulloblastoma, other high-risk brain tumor, and relapsed tumors were 50.0/81.8%, 87.5/85.7%, 66.7/88.9%, and 20.0/60.0%, respectively. CONCLUSIONS: Although tandem HDC/auto-SCT with TTC/MEC regimens showed promising survival rates, treatment modifications are warranted to reduce toxicities. The survival rates with relapsed brain tumors were unsatisfactory despite HDC/auto-SCT, and further study is needed.
Authors: Sarah C Clement; Antoinette Y N Schouten-van Meeteren; Leontien C M Kremer; A S Paul van Trotsenburg; Huib N Caron; Hanneke M van Santen Journal: Pediatr Blood Cancer Date: 2014-08-17 Impact factor: 3.167
Authors: Bekele Afessa; Raolat M Abdulai; Walter K Kremers; William J Hogan; Mark R Litzow; Steve G Peters Journal: Chest Date: 2011-07-21 Impact factor: 9.410
Authors: Anna M Butturini; Mary Jacob; Jennifer Aguajo; Noam A Vander-Walde; Judy Villablanca; Rima Jubran; Anat Erdreich-Epstein; Araz Marachelian; Girish Dhall; Jonathan L Finlay Journal: Cancer Date: 2009-07-01 Impact factor: 6.860
Authors: U Bode; M Zimmermann; O Moser; S Rutkowski; M Warmuth-Metz; T Pietsch; R D Kortmann; A Faldum; G Fleischhack Journal: J Neurooncol Date: 2014-09-02 Impact factor: 4.130
Authors: Adam Gassas; Hayley Craig-Barnes; Sharon D Dell; Peter Cox; Tal Schechter; John Doyle; Lillian Sung; Maarten Egeler; Nades Palaniyar Journal: Pediatr Transplant Date: 2013-03-06
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088